Dr. Reddy’s Laboratories Ltd announced the launch of the US Food and Drug Administration (FDA) approved trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules.
Dr Reddy’s trientine hydrochloride capsules USP, 250 mg are available in 100 count bottles.
Also read: Dr Reddy’s launches generic hypotensive injection
“We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head of Dr. Reddy’s North America Generics.
“Our product can be stored at room temperature (20°C to 25°C or 68° F to 77°F) throughout the product shelf life of 24 months.”
The Syprine brand and generic products had US sales or approximately US$ 94.2 million MAT for the most recent twelve months ending in December 2019, according toIQVIA.
Also read: Dr Reddy’s Labs launches generic injection for abortion in US
